Introduction
It is an honor to present this opening paper in the inaugural edition of of the journal Biomedical Glasses. This new Journal is timely. Numerous clinical applications in diverse fields routinely use bioactive glasses. Results are reported in a wide variety of journals. Having a journal devoted exclusively to the field will make it much easier to follow clinical performance and compare clinical findings. Likewise, many new concepts in the design and processing of inorganic glass-based bioactive materials, such as inorganicorganic hybrids, are being developed leading to the possibility of matching bio-mechanical properties of tissues and load bearing applications with biological properties. This journal will provide an excellent source of literature to follow development of these new bioactive materials. This new journal will also provide a standard source of literature to focus on new concepts of use of bioactive materials for tissue regeneration, as discussed below.
As the field moves forward we much remember that the purpose of all early, first generation, biomaterials was to replace diseased, damaged or ageing tissues. The materials were selected to match as closely as possible the physical properties of the replaced tissues with minimal toxic response in the host; ie. be as "bioinert" as possible. More than 50 types of implants made from 40 different first generation biomaterials are used annually to improve the quality of life of millions of people worldwide. This success clinically provides a standard for comparison of all new biomaterials, including medical glasses. However, large numbers of patients are now outliving prostheses made of first generation biomaterials.
A new approach to tissue repair or replacement is now possible through the concept of tissue regeneration. This concept of regeneration of tissues instead of replacing them is possible in part to the development of second and third generation bioactive materials, especially bioactive glasses. In 1969 began the development of second generation bioactive materials capable of bonding to hard and soft connective tissues [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] and third generation bioactive resorbable materials, specifically designed for tissue regeneration [14] [15] [16] [17] [18] [19] .
The objective of this paper is to review briefly the questions answered in three eras of development of bioactive glasses from the discovery in 1969 to the present, 2014. The three eras are; A) Era of Discovery, B) Era of Clinical Application, C) Era of Tissue Regeneration. Several important unanswered questions for the fourth era, D) Era of Innovation will also be suggested. Answers should appear in the journal in the years ahead. This finding was the basis for the first paper published in 1971 in the Journal of Biomedical Materials Research that summarised the in vivo results and the in vitro tests that provided an explanation for the interfacial bonding of the implant to bone [1] [2] [3] . The in vitro tests showed that the 45S5 Bioglass composition (see Table 1 ) developed a hydroxyapatite (HA) layer in test solutions. This HA phase developed on the surface of the implants in vitro was equivalent to the interfacial HA crystals observed in vivo by Dr Greenlee's transmission electron micrographs of the bonded interface. The HA crystals in vivo were bonded to layers of collagen fibrils produced at the interface by osteoblasts. The chemical bonding of the HA layer to collagen created the strongly bonded interface [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] .
The US Army Medical R and D Command continued funding of the project titled "An Investigation of Bonding Mechanisms at the Interface of a Prosthetic Material" for ten years. During that time a series of questions was addressed, raised by the discovery that interfacial bonding occurs between living tissues and non-living implant materials [11] . These questions are listed below with very brief summary answers. Most of these questions were answered during the decade from 1969 to 1979 with a multidisciplinary team of materials scientists, orthopaedic surgeons, dental researchers, biomechanics experts and biologists at the University of Florida, as summarized by Hench, Wilson and Greenspan in their comprehensive review, "Bioglass: A Short History and Bibliography" [11] .
A key review article that summarizes the answers to most of the questions listed above was published in 1982. It is reference 9; "Adhesion to Bone" by L.L. Hench [9, 11] . Part C reviews the data of Bonding of Mandibular and Maxillar Bone of Primates and Swine to Bioglass implants [9, 11] . A stable bone bonded implant in the anterior region of the mandible of a baboon after four years of functional use is presented in this paper, one of the longest in vivo studies of biomaterials in primates ever published [9] .
There are two important aspects of the questions explored in the Era of Discovery. First the methodology for investigating the reactive glass surface and bonded interfaces of bioactive implants with living tissues had to be developed as there was no precedence for such analyses. Thus, instrumental techniques such as infrared reflection spectroscopy, developed by Sanders and Hench, and applied to bioactive glasses was a critical part of this early effort as was cryogenic Auger electron spectroscopy (AES), developed by Ouichi, Pantano, Ogino and Hench [20] [21] [22] [23] . The extensive bibliography in the Hench, Wilson and Greenspan review provides the many citations that document the methods used to answer the questions listed below [11] .
The second aspect of this early era was an emphasis on questions related to use of bioactive glass or glassceramics as replacement body parts. Thus, tests were conducted primarily on bulk samples or as bioactive coatings on high strength metal, 316L or Co-Cr alloys, or ceramic, alumina, implants [11] [12] [13] . The questions assumed that the eventual applications of bioactive bonding would be to replace a diseased, damaged or missing part of the body. The second Era of Clinical Applications was based upon this knowledge.
Era of Discovery Questions
Answered:
(1) What is the physical, chemical and biological nature of the bioactive bond?
The interfacial bond between a bioactive glass and bone is composed of hydroxycarbonate apatite (HCA) crystals bonded to collagen fibers [1] [2] [3] .
(2) What are the mechanisms involved in formation of the bioactive bond?
A sequence of five surface reactions occur on the glass surface; [11] [12] [13] 
(3) How rapidly does the bioactive bond form?
The rate of bonding depends upon species of animal and location of implant. Bonding to rat femora occurs in days, bonding to primates, including humans occurs within weeks [9] .
(4) How thick is the bioactive bond?
The bond to bone is >100 micrometers within a few weeks and stabilizes at approximately 200-300 micrometers by approximately six months [24] .
(5) What is the mechanical strength of the bioactive bond?
The strength of the bond is equal or stronger than host bone [6, 9] .
(6) How mechanically rigid or compliant is the bioactive bond?
Due to microporosity of the thick silica gel and calcium phosphate bi-layer on the glass surface the interfacial bond has a gradient of elastic modulus from the glass to the tissue that mimics the gradient of elastic compliance between tendons and ligaments and bone [24] .
(7) How stable is the bioactive bond when exposed to aging or disease processes?
Limited experiments show that the bond when formed remains stable for many years [9, 11, 24] . 
Era of Innovation (2000-2020)
There are many challenges still ahead for the field of medical glasses that require advances in a fourth era; an era of innovation. Significant scientific and technological issues remain unanswered, such as:
1) Tissue engineered constructs for replacement of large bone defects have been investigated since the beginning of this era around year 2000 but are still not available as routine clinical products. Is it possible to achieve a stable vasculature in situ in tissue engineering constructs that can be maintained in culture before implantation or be generated in vivo following implantation? 2) Load bearing devices that can be used in orthopedics with long term, predictable reliability and bond to living bone without stress shielding are still not available cllinically. Is it feasible to produce and test bioactive implants that have predictable 20 year lifetime survivability under simulated load bearing physiological conditions? 3) Numerous soft tissue engineering applications have been investigated at an exploratory level but still require development into clinical products. Is it possible to obtain regulatory approval for clinical trials of soft tissue applications based upon limited in vitro and in vivo data and lack of understanding of basic biological mechanisms of soft tissue response to bioactive materials? 4) Control of stem cell technology to use with tissue engineering scaffolds is in its infancy. What are the fundamental mechanisms of stimulation of stem cell differentiation towards specific phenotypes and can these mechanisms be controlled to achieve greater than 99.999% accuracy to avoid potential tumourogenesis? 5) Design and production of bioactive materials with tailored bio-mechanical properties that are bioactive and rapidly incorporated with living tissue are exciting possibilities but can they be developed into clinical devices with predictable long term performance? 6) As discussed above, tissue regeneration via gene activation is a clinical reality that leads to enhanced osteogenesis but what are the fundamental mechanisms involved at the nucleus in the cell?
Conclusion
Until the questions related to the topics above, and more, are answered, applying the concept of bioactive ionic stimulation broadly to a wide range of regenerative medicine is largely trial and error. A general theory of bioactivity at the gene expression level still waits. The long term potential for new clinical applications for medical glasses is extraordinary. Achieving this potential is a great challenge with enormous socio-economic pay-off ahead. The need is great. The concepts and stimuli exist. The incentives are real. Will the field rise to meet this challenge? A challenge for authors of this journal is to avoid pursuing small incremental advancements in this exciting field. Instead, authors should to strive for unique and innovative approaches at a fundamental molecular biology level to create new bioactive materials and test them in representative biologicial conditions that mimic their use clinically. The goal must be to create materials that are revolutionary and can improve the quality of life and care for our ageing population without increasing the cost of care. This is a goal worth striving for and a vision that will last for decades.
